SMA vs. ABT, ISRG, BSX, SYK, MDT, BDX, EW, IDXX, RMD, and DXCM
Should you be buying Symmetry Medical stock or one of its competitors? The main competitors of Symmetry Medical include Abbott Laboratories (ABT), Intuitive Surgical (ISRG), Boston Scientific (BSX), Stryker (SYK), Medtronic (MDT), Becton, Dickinson and Company (BDX), Edwards Lifesciences (EW), IDEXX Laboratories (IDXX), ResMed (RMD), and DexCom (DXCM). These companies are all part of the "health care equipment" industry.
Symmetry Medical vs.
Abbott Laboratories (NYSE:ABT) and Symmetry Medical (NYSE:SMA) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, media sentiment, earnings, risk, community ranking and dividends.
75.2% of Abbott Laboratories shares are held by institutional investors. 0.5% of Abbott Laboratories shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
In the previous week, Abbott Laboratories had 52 more articles in the media than Symmetry Medical. MarketBeat recorded 54 mentions for Abbott Laboratories and 2 mentions for Symmetry Medical. Abbott Laboratories' average media sentiment score of 1.33 beat Symmetry Medical's score of 0.00 indicating that Abbott Laboratories is being referred to more favorably in the media.
Abbott Laboratories has a net margin of 31.95% compared to Symmetry Medical's net margin of 0.00%. Abbott Laboratories' return on equity of 20.74% beat Symmetry Medical's return on equity.
Abbott Laboratories received 815 more outperform votes than Symmetry Medical when rated by MarketBeat users. However, 82.53% of users gave Symmetry Medical an outperform vote while only 70.00% of users gave Abbott Laboratories an outperform vote.
Abbott Laboratories presently has a consensus target price of $142.59, indicating a potential upside of 7.37%. Symmetry Medical has a consensus target price of $38.50, indicating a potential upside of 5.48%. Given Abbott Laboratories' higher possible upside, analysts plainly believe Abbott Laboratories is more favorable than Symmetry Medical.
Abbott Laboratories has higher revenue and earnings than Symmetry Medical.
Summary
Abbott Laboratories beats Symmetry Medical on 11 of the 14 factors compared between the two stocks.
Get Symmetry Medical News Delivered to You Automatically
Sign up to receive the latest news and ratings for SMA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Symmetry Medical Competitors List
Related Companies and Tools
This page (NYSE:SMA) was last updated on 5/30/2025 by MarketBeat.com Staff
